ArticleJournal for immunotherapy of cancer2023

AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors.

Sophia Frentzas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.